Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
- Caroli A *Medical Imaging Unit, Biomedical Engineering Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo †Laboratory of Epidemiology and Neuroimaging, IRCCS Fatebenefratelli, Brescia §Department of Decision Science, Bocconi University, Milan, Italy ‡Department of Engineering, University of Cambridge **Institute of Brain, Behaviour, and Mental Health University of Cambridge, Cambridge ∥Banner Alzheimer's Institute, Phoenix, AZ ¶Helen Wills Neuroscience Institute, University of California, Berkeley, CA #Hannover Medical School, Clinic for Nuclear Medicine, Hannover, Germany ††Departments of Internal Medicine and Psychiatry, University Hospitals and University of Geneva, Geneva, Switzerland.
- Prestia A
- Wade S
- Chen K
- Ayutyanont N
- Landau SM
- Madison CM
- Haense C
- Herholz K
- Reiman EM
- Jagust WJ
- Frisoni GB
- 2014-12-02
Published in:
- Alzheimer disease and associated disorders. - 2015
Aged
Aged, 80 and over
Alzheimer Disease
Amyloid beta-Peptides
Atrophy
Biomarkers
Brain
Clinical Trials as Topic
Cognition
Cognitive Dysfunction
Cohort Studies
Disease Progression
Female
Fluorodeoxyglucose F18
Hippocampus
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Neuropsychological Tests
Outcome Assessment, Health Care
Peptide Fragments
Positron-Emission Tomography
Radiopharmaceuticals
English
BACKGROUND
The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI).
METHODS
Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms.
RESULTS
Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency.
CONCLUSION
These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI).
METHODS
Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms.
RESULTS
Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency.
CONCLUSION
These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1097/WAD.0000000000000071
- PMID 25437302
- Persistent URL
- https://sonar.ch/global/documents/38872
Statistics
Document views: 19
File downloads:
- fulltext.pdf: 0